While Western biohackers were rediscovering peptides in the 2010s, Soviet researchers had already run decades of clinical research on bioregulatory peptides. The work of Vladimir Khavinson — a Russian gerontologist who began this research in the 1970s — produced a family of short peptides called ‘bioregulators’ that function as tissue-specific gene expression regulators. Vilon is the bioregulator derived from thymic and lymphatic tissue, targeting the immune system’s structural regulation.
What Is Vilon?
Vilon is a dipeptide — just two amino acids: Lys-Glu (lysine-glutamic acid). Despite its simplicity, Vilon has documented biological activity that is surprisingly broad. Its dipeptide structure provides: high stability (resistance to peptidase degradation), excellent tissue penetration, no immunogenicity (too small to trigger immune reaction), and some oral bioavailability (though SC injection achieves better plasma levels).
Mechanisms of Action
Immune Regulation: The thymus — where T lymphocytes mature — involutes dramatically with age, reducing T-cell output and diversity. Vilon stimulates thymic epithelial cells and restores thymopoiesis (T-cell generation) in aged organisms. It also enhances T-cell surface receptor expression, improves T-cell activation responses in aged lymphocytes, increases NK cell cytotoxic activity, and helps restore Treg function for preventing autoimmunity and resolving inflammation.
NF-κB Modulation: Chronic NF-κB activation drives ‘inflammaging’ — the low-grade chronic inflammation that accelerates aging across every organ system. Vilon normalizes NF-κB activity in aged immune cells, reducing inflammatory tone without full immunosuppression.
Antioxidant Upregulation: Vilon increases expression of superoxide dismutase (SOD) and catalase — the primary intracellular antioxidant enzymes — reducing oxidative stress in immune cells and adjacent tissue.
p53 and Apoptosis Regulation: Modulates p53-dependent apoptosis in immune cells — reducing excess apoptosis in functional lymphocytes while supporting clearance of damaged cells.
This precise, multi-pathway regulation of fundamental cellular processes is a textbook example of the Tony Huge Laws of Biochemistry Physics in action, demonstrating how a minimal molecular signal can orchestrate complex systemic rejuvenation.
The Soviet Clinical Data
In elderly patients, 10-day Vilon courses significantly increased T-lymphocyte count, NK cell activity, and serum immunoglobulin levels. A 15-year longevity study found annual Vilon treatment reduced mortality by approximately 20-25% compared to control groups. Vilon improved clinical outcomes in cancer patients undergoing chemotherapy by restoring immune function. Seasonal use reduced respiratory infection incidence and severity in elderly subjects. These are not small, single studies — the Khavinson program produced hundreds of peer-reviewed publications across decades. The relative obscurity in the West is a language and geopolitical artifact, not a reflection of evidence quality.
Vilon vs Thymalin
Both are thymus-derived bioregulators. Thymalin is a polypeptide extract acting more broadly on thymic function with strong T-cell differentiation effects. Vilon (Lys-Glu) is a dipeptide acting specifically on immune cell gene expression regulation and NF-κB modulation, with stronger documented effects on inflammation resolution and NK cell activation. The two are often used in rotation. See Thymalin: Russian Bioregulator for Immune Rebuilding.
Dosing Protocol
Standard (SC injection): 1-2mg once daily for 10 consecutive days. Frequency: 2-4 courses per year (typically spring and fall). Oral/Sublingual: 2-5mg sublingually once daily for 10-20 days. Lower bioavailability but documented activity at higher doses.
Annual Bioregulator Rotation: Spring: Vilon (immune) + Epitalon (pineal/circadian). Summer: Pinealon (neuroprotection). Fall: Thymalin (broader immune) + Vilon. Winter: Vesugen (vascular) + Vilon.
Safety Profile
No documented serious adverse events in the clinical literature at standard doses. Mild injection site reactions possible. Theoretical caution in active autoimmune disease (stimulating immune function could worsen activity). Its size (dipeptide) and natural occurrence make allergic reactions unlikely. Decades of clinical use confirm a favorable safety profile.
The Complete Immune Optimization Stack
Foundation: Vitamin D3 at 60-80 ng/mL (Vitamin D3 + K2 Protocol), Zinc 15-30mg, optimal sleep (Sleep Protocol). Peptide support: Thymosin Alpha-1 quarterly cycles (Thymosin Alpha-1). Bioregulators: Vilon 1-2mg x 10 days (2x/year), Thymalin 10mg x 10 days (2x/year). Senolytic support: quarterly senolytic cycle to clear dysfunctional immune cells and allow regeneration. The Enhanced Man has the intellectual humility to look beyond his cultural bubble and the analytical sophistication to evaluate evidence on its merits — regardless of where it came from. Explore the full framework at the Enhanced Athlete Protocol.
Interesting Perspectives
While the primary research focuses on immune restoration, the implications of Vilon’s mechanism extend into unconventional territories. Its role in modulating NF-κB—a master regulator of inflammation and cellular stress responses—suggests potential applications beyond immunology. For instance, chronic, low-grade NF-κB activation is a key driver of metabolic dysfunction and neuroinflammation. Biohackers are exploring whether Vilon’s anti-inflammatory action could provide ancillary benefits for cognitive longevity and metabolic health, acting as a systemic “inflammation reset” switch. Furthermore, its stimulation of thymic epithelial cells hints at a role in tissue regeneration paradigms, potentially synergizing with other rejuvenation strategies like senolytics to clear aged tissue and promote youthful regrowth. The concept of using a simple dipeptide to provide a foundational “youthful signal” to the immune system, rather than aggressively stimulating it, represents a paradigm shift from Western immunology’s often blunt-force approaches.
Related Video: The Timeline of My Immune Peptide Experiment
Related Video: I Had the Worst Side Effects From This Peptide
Citations & References
Note: The primary clinical literature on Khavinson peptides like Vilon is extensive but largely published in Russian-language journals. The following represent key studies and reviews that have been translated or cited in international contexts, highlighting the peptide’s mechanism and observed effects.
- Khavinson, V. Kh., & Malinin, V. V. (2005). Gerontological aspects of genome peptide regulation. Basel: Karger. (This monograph outlines the foundational theory and decades of research behind bioregulators like Vilon).
- Khavinson, V. Kh., et al. (2002). Peptide promotes extension of human life span and slows down aging. Bulletin of Experimental Biology and Medicine, 133(2), 122-124. (Longevity study associated with bioregulator use).
- Khavinson, V. Kh., et al. (2003). Effect of vilon on biological age and lifespan in mice. Bulletin of Experimental Biology and Medicine, 136(6), 572-575. (Preclinical evidence of lifespan extension).
- Anisimov, V. N., et al. (2002). Effect of peptide bioregulators on life span and tumor development in animals. Advances in Gerontology, 10, 74-84. (Review of geroprotective and oncopreventive effects).
- Kozina, L. S., et al. (2007). Influence of vilon on the immune status of patients with lung cancer. Bulletin of Experimental Biology and Medicine, 144(3), 368-371. (Clinical study on immune restoration in cancer patients).
- Khavinson, V. Kh., & Morozov, V. G. (2003). Peptides of pineal gland and thymus prolong human life. Neuroendocrinology Letters, 24(3-4), 233-240. (Review of clinical effects on aging and immunity).
- Lezhava, T. A., et al. (2007). Effect of vilon on the chromatin activation in lymphocytes from old people. Bulletin of Experimental Biology and Medicine, 143(1), 136-138. (Mechanistic study on gene expression in aged immune cells).